IRLAB receives approval from the Finnish MPA (Fimea)

October 5, 2017

IRLAB Therapeutics AB has now received approval from Fimea (the Finnish MPA) and the Ethics Committee at the University hospital in Turkku to conduct the Phase II clinical trial with IRL752 in Finland. On august 25, 2017, IRLAB received approval from the Swedish MPA to start the study in Sweden. 

For full press release click here for English version and click here for Swedish version.